Boston’s heavyweight cancer centers are scrambling to spot tumors as early as possible, and to build clinics, research programs, and new revenue streams around that push. Mass General Brigham and Dana-Farber have both rolled out expanded early detection efforts, even as doctors and health economists warn that more testing can mean more costs and more procedures that may not actually help people live longer. For local patients, the uncomfortable question is simple: when does finding cancer sooner slide into overdiagnosis?
Hospitals Build Early Detection Hubs
In March 2025, Mass General Brigham said it would put roughly $400 million over four years into boosting outpatient capacity for its cancer institute, including renovations at Brigham and Women’s Hospital. The system says the money will go toward new clinical space, technology, and staffing as part of a broader push to build out outpatient care and research infrastructure, according to Mass General Brigham.
That strategy explicitly includes catching disease earlier. The Mass General Brigham Cancer Institute highlights an Early Detection and Diagnostics Program, with clinics in Waltham and at the Brigham in Longwood, designed to funnel patients into screening, risk assessment, and related research.
Big Gifts, Big Questions
Dana-Farber has been shoring up the early detection side as well. In April, the institute announced a $5 million gift from Larry and Susan Marx to support cancer prevention and early detection, a package that includes a named chair and added research funding. In a release from Dana-Farber, leaders said the money will help scale studies at the Centers for Early Detection and Interception and broaden access to screening-focused research.
The message is clear: if there is a promising test, these centers want to be the place where you get it, and where the underlying science gets done.
Promise And The Numbers
Investors and health systems see real money in multi-cancer early detection tests. Market researchers at Grand View Research project the sector will grow to about $2.86 billion by 2030, driven by rapid development of blood-based assays and liquid-biopsy platforms…